BrightPath Biotherapeutics Co (TSE:4594) Operating Margin %: 700,927.78% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
35 GF Score
Price 円53.00
! 3 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co Operating Margin %?

BrightPath Biotherapeutics Co TSE:4594 35 Operating Margin % is 700,927.78% as of Mar. 2026. GuruFocus rates TSE:4594 with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, BrightPath Biotherapeutics Co ranks worse than 100% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. BrightPath Biotherapeutics Co's Operating Income for the three months ended in Mar. 2026 was 円126.17 Mil. BrightPath Biotherapeutics Co's Revenue for the three months ended in Mar. 2026 was 円0.02 Mil. Therefore, BrightPath Biotherapeutics Co's Operating Margin % for the quarter that ended in Mar. 2026 was 700,927.78%.

Warning Sign:

BrightPath Biotherapeutics Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -114.3%.

The historical rank and industry rank for BrightPath Biotherapeutics Co's Operating Margin % or its related term are showing as below:

TSE:4594' s Operating Margin % Range Over the Past 10 Years
Min: -2221761.29   Med: -21978.23   Max: -210.26
Current: -2221761.29


TSE:4594's Operating Margin % is ranked worse than
100% of 942 companies
in the Biotechnology industry
Industry Median: -81.01 vs TSE:4594: -2221761.29

BrightPath Biotherapeutics Co's 5-Year Average Operating Margin % Growth Rate was -114.30% per year.

BrightPath Biotherapeutics Co's Operating Income for the three months ended in Mar. 2026 was 円126.17 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was 円-1,377.49 Mil.


BrightPath Biotherapeutics Co  (TSE:4594) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


BrightPath Biotherapeutics Co Operating Margin % Related Terms


BrightPath Biotherapeutics Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for BrightPath Biotherapeutics Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrightPath Biotherapeutics Co Operating Margin % Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,579.65 -27,785.21 -1,604,276.39 -102,464.08 -1,541,667.86

BrightPath Biotherapeutics Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -743,484.85 0.00 -2,898,766.67 700,927.78 -4,973,327.27

TSE:4594 vs VRTX, REGN, RVMD: Operating Margin % Comparison

For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrightPath Biotherapeutics Co Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where BrightPath Biotherapeutics Co's Operating Margin % falls into.


TSE:4594
35GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BrightPath Biotherapeutics Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BrightPath Biotherapeutics Co's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (A: Mar. 2026 ) / Revenue (A: Mar. 2026 )
=-1295.001 / 0.084
=-1,541,667.86 %

BrightPath Biotherapeutics Co's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=126.167 / 0.018
=700,927.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 700,927.78% mean?
BrightPath Biotherapeutics Co (TSE:4594) has a Operating Margin % of 700,927.78% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on BrightPath Biotherapeutics Co and its competitors. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #942 out of 942 companies in the Biotechnology industry.
Is BrightPath Biotherapeutics Co's Operating Margin % too high?
BrightPath Biotherapeutics Co's current Operating Margin % is 700,927.78%. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #942 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #942 out of 942 companies for Operating Margin %. This places BrightPath Biotherapeutics Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on BrightPath Biotherapeutics Co and its competitors. BrightPath Biotherapeutics Co's current Operating Margin % is 700,927.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
BrightPath Biotherapeutics Co (TSE:4594) has a current Operating Margin % of 700,927.78%. The current Operating Margin % is 700,927.78%. BrightPath Biotherapeutics Co's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Operating Margin % is 700,927.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
35GF Score

Get the complete analysis for TSE:4594

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円53.00
Price